Reaction
Mantle Cell Lymphoma Recurrent reporting signals
As of the last recalculation, Mantle Cell Lymphoma Recurrent appears in 423 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is BENDAMUSTINE HYDROCHLORIDE (PRR 276.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Bendamustine Hydrochloride | 58 | 276.0 | 277.4 |
| Bendamustine Hcl | 55 | 200.5 | 201.2 |
| Rituximab | 263 | 160.2 | 160.4 |
| Ibrutinib | 162 | 159.3 | 159.6 |
| Cytarabine | 125 | 144.9 | 145.2 |
| Doxorubicin Hydrochloride | 72 | 130.5 | 130.8 |
| Doxorubicin | 147 | 123.9 | 124.1 |
| Vincristine Sulfate | 56 | 108.2 | 108.4 |
| Acalabrutinib | 24 | 103.2 | 103.4 |
| Cyclophosphamide Injection, Solution | 190 | 95.1 | 95.2 |
| Cyclophosphamide | 190 | 95.1 | 95.2 |
| Cyclophosphamide For Injection | 190 | 95.1 | 95.2 |
| Melphalan | 37 | 87.6 | 87.8 |
| Melphalan Hydrochloride | 37 | 79.5 | 79.6 |
| Mesna Injection | 11 | 67.2 | 67.3 |
| Mesna | 11 | 66.0 | 66.1 |
| Fludarabine Phosphate | 45 | 62.9 | 63.0 |
| Venetoclax | 56 | 51.4 | 51.5 |
| Etoposide | 58 | 44.8 | 44.9 |
| Valacyclovir | 34 | 43.5 | 43.6 |
| Cisplatin | 58 | 42.2 | 42.2 |
| Obinutuzumab | 12 | 36.9 | 36.9 |
| Thiotepa | 5 | 26.1 | 26.1 |
| Ifosfamide | 10 | 23.4 | 23.4 |